The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1
Open accessAbstract
People with neurofibromatosis 1 (NF1) have multiple benign neurofibromas and a 10% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNSTs). Most MPNSTs develop from benign plexiform neurofibromas, so the burden of benign tumors may be a risk factor for developing MPNST. We studied 13 NF1 patients with MPNSTs and 26 age- and sex-matched controls (NF1 patients who did not have MPNSTs) with detailed clinical examinations and whole-body MRI to characterize their body burden of internal benign neurofibromas. Internal plexiform neurofibromas were identified in 22 (56%) of the 39 NF1 patients studied. All six of the NF1 patients with MPNSTs under 30 years of age had neurofibromas visualized on whole-body MRI, compared to only 3 of 11 matched NF1 controls under age 30 (p < 0.05). Both the median number of plexiform neurofibromas (p < 0.05) and the median neurofibroma volume (p < 0.01) on whole-body MRI were significantly greater among MPNST patients younger than 30 years of age than among controls. No significant differences in whole-body MRI findings were observed between NF1 patients with MPNSTs and controls who were 30 years of age or older. Whole-body MRI of NF1 patients allows assessment of the burden of internal neurofibromas, most of which are not apparent on physical examination. Whole-body imaging of young NF1 patients may allow those at highest risk for developing MPNST to be identified early in life. Close surveillance of these high-risk patients may permit earlier diagnosis and more effective treatment of MPNSTs that develop.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases
Ducatman, B. S., Scheithauer, B. W., Piepgras, D. G., Reiman, H. M., & Ilstrup, D. M. (1986) · Cancer · doi:10.1002/1097-0142(19860515)57:10<2006::aid-cncr2820571022>3.0.co;2-6 · Cited by 1,581
Neurofibromatosis: Conference Statement
(1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520290115023 · Cited by 1,547
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
Neurofibromatosis, Phenotype, Natural History, and Pathogenesis
Riccardi, V. M., & Smirniotopoulos, J. (1992) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199211000-00009 · Cited by 893
(1988) · PubMed · Cited by 817
Mortality in Neurofibromatosis 1: An Analysis Using U.S. Death Certificates
Rasmussen, S. A., Yang, Q., & Friedman, J. M. (2001) · The American Journal of Human Genetics · doi:10.1086/320121 · Cited by 530
Self-citationNeurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective
Ferner, R. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70075-3 · Cited by 511
Association between benign and malignant peripheral nerve sheath tumors in NF1
Tucker, T., Wolkenstein, P., Revuz, J., Zeller, J., & Friedman, J. M. (2005) · Neurology · doi:10.1212/01.wnl.0000168830.79997.13 · Cited by 311
Self-citationElevated Risk for MPNST in NF1 Microdeletion Patients
De Raedt, T., Brems, H., Wolkenstein, P., Vidaud, D., Pilotti, S., Perrone, F., Mautner, V., Frahm, S., Sciot, R., & Legius, E. (2003) · The American Journal of Human Genetics · doi:10.1086/374821 · Cited by 310
Self-citation
Cited by
Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.4 · Cited by 862
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Gross, A. M., Wolters, P. L., Dombi, E., Baldwin, A., Whitcomb, P., Fisher, M. J., Weiss, B., Kim, A., Bornhorst, M., Shah, A. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912735 · Cited by 726
Self-citationActivity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Dombi, E., Baldwin, A., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L. E., Rizvi, T. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605943 · Cited by 682
Self-citationClinical and genetic aspects of neurofibromatosis 1
Jett, K., & Friedman, J. M. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181bf15e3 · Cited by 501
Self-citationRAS and beyond: the many faces of the neurofibromatosis type 1 protein
Anastasaki, C., Orozco, P., & Gutmann, D. H. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049362 · Cited by 86
Metadata
- Authors
- Mautner, V.-F., Asuagbor, F. A., Dombi, E., Fünsterer, C., Kluwe, L., Wenzel, R., Widemann, B. C., & Friedman, J. M.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08-01
- Volume
- 10
- Issue
- 4
- Pages
- 593-598
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2130848213
- Cited by
- 260
- References
- 33
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. https://app.cochat.ai/papers/10.1215/15228517-2008-011
- The paper
- Mautner, V.-F., Asuagbor, F. A., Dombi, E., Fünsterer, C., Kluwe, L., Wenzel, R., Widemann, B. C., & Friedman, J. M. (2008). Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro-Oncology. https://doi.org/10.1215/15228517-2008-011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.